Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <= 30%
link https://doi.org/10.1016/j.ejheart.2005.11.008account_box Pitt, Baccount_box Gheorghiade, Maccount_box Zannad, Faccount_box Anderson, JLaccount_box van Veldhuisen, DJaccount_box Parkhomenko, Aaccount_box Corbalan, Raccount_box Klug, EQaccount_box Mukherjee, Raccount_box Solomon, Haccount_box EPHESUS Invest
Comparte este registro
Aims: Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF <= 30% at baseline was conducted to determine the value of eplerenone in this setting.
Registro Sencillo
Registro Completo
| Autor | Pitt, B Gheorghiade, M Zannad, F Anderson, JL van Veldhuisen, DJ Parkhomenko, A Corbalan, R Klug, EQ Mukherjee, R Solomon, H EPHESUS Invest |
| Título | Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <= 30% |
| Revista | EUROPEAN JOURNAL OF HEART FAILURE |
| ISSN | 1388-9842 |
| Volumen | 8 |
| Número de publicación | 3 |
| Página inicio | 295 |
| Página final | 301 |
| Fecha de publicación | 2006 |
| Resumen | Aims: Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF <= 30% at baseline was conducted to determine the value of eplerenone in this setting. Methods and results: In EPHESUS, 6632 patients with LVEF <= 40% and clinical heart failure (HF) post-AMI who were receiving standard therapy were randomized to eplerenone 25 mg/day titrated to 50 mg/day or placebo for a mean follow-up of 16 months. Treatment with eplerenone in the subgroup of patients with LVEF <= 30% (N = 2106) resulted in relative risk reductions of 21% versus placebo in both all-cause mortality (P=0.012) and cardiovascular (CV) mortality/CV hospitalization (P=0.001), and 23% for CV mortality (P=0.008). The relative risk of sudden cardiac death (SCD) was reduced 33% (P=0.01) and HF mortality/HF hospitalization was reduced 25% (P=0.005) with eplerenone compared with placebo. Within 30 days of randomization, eplerenone resulted in relative risk reductions of 43% for all-cause mortality (P=0.002), 29% for CV mortality/CV hospitalization (P=0.006), and 58% for SCD (P=0.008). Conclusions: Treatment with eplerenone plus standard therapy in patients with post-AMI HF and LVEF <= 30% provided significant incremental benefits in reducing both early and late mortality and morbidity. (c) 2005 European Society of Cardiology Published by Elsevier B.V. All rights reserved. |
| Derechos | acceso abierto |
| DOI | 10.1016/j.ejheart.2005.11.008 |
| Editorial | ELSEVIER SCIENCE BV |
| Enlace | |
| Id de publicación en Pubmed | MEDLINE:16504579 |
| Id de publicación en WoS | WOS:000238089400012 |
| Paginación | 7 páginas |
| Palabra clave | aldosterone heart failure left ventricular systolic dysfunction eplerenone EPHESUS ACUTE MYOCARDIAL-INFARCTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR SELECTIVE ALDOSTERONE BLOCKER HEART-RATE-VARIABILITY OXIDATIVE STRESS SPIRONOLACTONE FAILURE DYSFUNCTION PREVENTS |
| Tema ODS | 03 Good Health and Well-being |
| Tema ODS español | 03 Salud y bienestar |
| Tipo de documento | artículo |